Company intelligence / Profile preview

Genpharm

Dubai, United Arab Emirates

Ownership: Private
Development stage: Other

Overview

Genpharm is a leading regional commercialization partner specializing in rare diseases and specialty drugs, being the first to introduce gene therapy in the MENAT region. It partners with global biotech leaders to accelerate access to innovative therapies for rare disorders, with a particular focus on early and accurate diagnosis, and has commercial agreements to distribute products from companies including Novartis Gene Therapies, Orchard Therapeutics, PTC, Amicus, Sarepta, and others[1][2][5].

Therapeutic areas: OphthalmologyRare DiseasesGastroenterologyDermatologyNeurology
Modalities: Gene therapyCell therapySmall moleculeBiologic
Industry: Consulting

Partnerships

Novartis Gene TherapiesOrchard TherapeuticsPTCAmicus TherapeuticsSarepta TherapeuticsUltragenyxAlbireoQuoinArgenxBiohaven PharmaceuticalsApellis Pharmaceuticals

Beyond the preview

Go deeper on Genpharm.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Genpharm.

Explore the full profile